| Name | Title | Contact Details |
|---|
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective measures, as well as top-rated ambulatory surgery centers. Plan members gain access to some of the best providers in the country, with little to no out-of-pocket expense. They receive concierge-level service, with a personal care coordinator to assist them every step of the way. They also have access to unbiased decision support tools to help them with second opinions, alternative treatments, and provider selection. Plan sponsors recognize significant cost savings, increased engagement, and increased productivity, along with recruitment and retention advantages, by offering a benefit that improves outcomes and reduces costs.
Shawnee Mission Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Shawnee Mission Medical Center is based in Overland Park, KS. You can find more information on Shawnee Mission Medical Center at www.shawneemission.org
EXIM-INDIS is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tethys Bioscience is a personalized predictive medicine company developing novel tests which address the growing global healthcare challenge of chronic diseases such as diabetes.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III